A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry

Funding Open Access funding enabled and organized by Projekt DEAL. BCAC is funded by the European Union's Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), and the PERSPECTIVE I&I project, funded by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the Ministère de l’Économie et de l'Innovation du Québec through Genome Québec, the Quebec Breast Cancer Foundation. The EU Horizon 2020 Research and Innovation Programme funding source had no role in study design, data collection, data analysis, data interpretation or writing of the report. Additional funding for BCAC is provided via the Confluence project which is funded with intramural funds from the National Cancer Institute Intramural Research Program, National Institutes of Health. Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and Cancer Research UK Grant C1287/A16563 and the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344) and, the Ministère de l’Économie, Science et Innovation du Québec through Genome Québec and the PSRSIIRI-701 grant, and the Quebec Breast Cancer Foundation. Funding for iCOGS came from: the European Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009–223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112—the GAME-ON initiative), the Department of Defence (W81XWH-10–1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, and Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The BRIDGES panel sequencing was supported by the European Union Horizon 2020 research and innovation program BRIDGES (grant number, 634935) and the Wellcome Trust (v203477/Z/16/Z). The Australian Breast Cancer Family Study (ABCFS) was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow. M.C.S. is a NHMRC Senior Research Fellow. The ABCS study was supported by the Dutch Cancer Society [grants NKI 2007–3839; 2009 4363]. The Australian Breast Cancer Tissue Bank (ABCTB) was supported by the National Health and Medical Research Council of Australia, The Cancer Institute NSW and the National Breast Cancer Foundation. The AHS study is supported by the intramural research program of the National Institutes of Health, the National Cancer Institute (grant number Z01-CP010119), and the National Institute of Environmental Health Sciences (grant number Z01-ES049030). The work of the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. The BCEES was funded by the National Health and Medical Research Council, Australia and the Cancer Council Western Australia and acknowledges funding from the National Breast Cancer Foundation (JS). For the BCFR-NY, BCFR-PA, BCFR-UT this work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. The BCINIS study is supported in part by the Breast Cancer Research Foundation (BCRF). The BREast Oncology GAlician Network (BREOGAN) is funded by Acción Estratégica de Salud del Instituto de Salud Carlos III FIS PI12/02125/Cofinanciado and FEDER PI17/00918/Cofinanciado FEDER; Acción Estratégica de Salud del Instituto de Salud Carlos III FIS Intrasalud (PI13/01136); Programa Grupos Emergentes, Cancer Genetics Unit, Instituto de Investigacion Biomedica Galicia Sur. Xerencia de Xestion Integrada de Vigo-SERGAS, Instituto de Salud Carlos III, Spain; Grant 10CSA012E, Consellería de Industria Programa Sectorial de Investigación Aplicada, PEME I + D e I + D Suma del Plan Gallego de Investigación, Desarrollo e Innovación Tecnológica de la Consellería de Industria de la Xunta de Galicia, Spain; Grant EC11-192. Fomento de la Investigación Clínica Independiente, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain; and Grant FEDER-Innterconecta. Ministerio de Economia y Competitividad, Xunta de Galicia, Spain. CBCS is funded by the Canadian Cancer Society (grant # 313404) and the Canadian Institutes of Health Research. CCGP is supported by funding from the University of Crete. The CECILE study was supported by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Agence Nationale de Sécurité Sanitaire, de l'Alimentation, de l'Environnement et du Travail (ANSES), Agence Nationale de la Recherche (ANR). The CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Herlev and Gentofte Hospital. The CNIO-BCS was supported by the Instituto de Salud Carlos III, the Red Temática de Investigación Cooperativa en Cáncer and grants from the Asociación Española Contra el Cáncer and the Fondo de Investigación Sanitario (PI11/00923 and PI12/00070). The American Cancer Society funds the creation, maintenance, and updating of the CPS-II cohort. The California Teachers Study (CTS) and the research reported in this publication were supported by the National Cancer Institute of the National Institutes of Health under award number U01-CA199277; P30-CA033572; P30-CA023100; UM1-CA164917; and R01-CA077398. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. The collection of cancer incidence data used in the California Teachers Study was supported by the California Department of Public Health pursuant to California Health and Safety Code Sect. 103885; Centers for Disease Control and Prevention’s National Program of Cancer Registries, under cooperative agreement 5NU58DP006344; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute. The opinions, findings, and conclusions expressed herein are those of the author(s) and do not necessarily reflect the official views of the State of California, Department of Public Health, the National Cancer Institute, the National Institutes of Health, the Centers for Disease Control and Prevention or their Contractors and Subcontractors, or the Regents of the University of California, or any of its programs. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). The ESTHER study was supported by a grant from the Baden Württemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). PROCAS thank NIHR for funding. The GENICA was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, as well as the Department of Internal Medicine, Johanniter GmbH Bonn, Johanniter Krankenhaus, Bonn, Germany. The GESBC was supported by the Deutsche Krebshilfe e. V. [70492] and the German Cancer Research Center (DKFZ). The KARMA study was supported by Märit and Hans Rausings Initiative Against Breast Cancer. The KBCP was financially supported by the special Government Funding (VTR) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, and by the strategic funding of the University of Eastern Finland. kConFab is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. Financial support for the AOCS was provided by the United States Army Medical Research and Materiel Command [DAMD17-01–1-0729], Cancer Council Victoria, Queensland Cancer Fund, Cancer Council New South Wales, Cancer Council South Australia, The Cancer Foundation of Western Australia, Cancer Council Tasmania and the National Health and Medical Research Council of Australia (NHMRC; 400413, 400281, 199600). G.C.T. and P.W. are supported by the NHMRC. RB was a Cancer Institute NSW Clinical Research Fellow. LMBC is supported by the 'Stichting tegen Kanker'. DL is supported by the FWO. The MARIE study was supported by the Deutsche Krebshilfe e.V. [70–2892-BR I, 106332, 108253, 108419, 110826, 110828], the Hamburg Cancer Society, the German Cancer Research Center (DKFZ) and the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. The MCBCS was supported by the NIH grants R35CA253187, R01CA192393, R01CA116167, R01CA176785 a NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [P50CA116201], and the Breast Cancer Research Foundation. The Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 396414 and 1074383 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database. The MEC was supported by NIH Grants CA63464, CA54281, CA098758, CA132839 and CA164973. The MISS study was supported by funding from ERC-2011-294576 Advanced grant, Swedish Cancer Society CAN 2018/675, Swedish Research Council, Local hospital funds, Berta Kamprad Foundation FBKS 2021–19, Gunnar Nilsson. The MMHS study was supported by NIH grants CA97396, CA128931, CA116201, CA140286 and CA177150. MSKCC is supported by grants from the Breast Cancer Research Foundation and Robert and Kate Niehaus Clinical Cancer Genetics Initiative. The NBHS was supported by NIH grant R01CA100374. Biological sample preparation was conducted the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485. The Northern California Breast Cancer Family Registry (NC-BCFR) and Ontario Familial Breast Cancer Registry (OFBCR) were supported by grant U01CA164920 from the USA National Cancer Institute of the National Institutes of Health. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. The Carolina Breast Cancer Study (NCBCS) was funded by Komen Foundation, the National Cancer Institute (P50 CA058223, U54 CA156733, U01 CA179715), and the North Carolina University Cancer Research Fund. The NHS was supported by NIH grants P01 CA87969, UM1 CA186107, and U19 CA148065. The NHS2 was supported by NIH grants UM1 CA176726 and U19 CA148065. The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. Genotyping for PLCO was supported by the Intramural Research Program of the National Institutes of Health, NCI, Division of Cancer Epidemiology and Genetics. The PLCO is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health. The SASBAC study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation. The SBCS was supported by Sheffield Experimental Cancer Medicine Centre and Breast Cancer Now Tissue Bank. SEARCH is funded by Cancer Research UK [C490/A10124, C490/A16561] and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The University of Cambridge has received salary support for PDPP from the NHS in the East of England through the Clinical Academic Reserve. The Sister Study (SISTER) is supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES044005 and Z01-ES049033). The SMC is funded by the Swedish Cancer Foundation and the Swedish Research Council (VR 2017–00644) grant for the Swedish Infrastructure for Medical Population-based Life-course Environmental Research (SIMPLER). The USRT Study was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The WHI program is funded by the National Heart, Lung, and Blood Institute, the US National Institutes of Health and the US Department of Health and Human Services (HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C and HHSN271201100004C). This work was also funded by NCI U19 CA148065-01.Peer reviewedPublisher PD

DECLARACIÓN DE BUENOS AIRES. Innovación inclusiva: innovación social, innovación pública e innovación financiera

La presente declaración es fruto del congreso «Dinámicas de la Innovación Social: innovación financiera, innovación social e innovación en el sector público», realizado en Buenos Aires los días 11 y 12 de diciembre de 2014, organizado por el Instituto de Investigación en Administración, Contabilidad y Métodos Cuantitativos para la Gestión (IADCOM) de la Universidad de Buenos Aires y el Centro de Innovación Social (SINNERGIAK Social Innovation) de la Universidad del País Vasco

A new neolepadid cirripede from a Pleistocene cold seep, Krishna-Godavari Basin, offshore India

Valves of a thoracican cirripede belonging to a new species of the Neolepadidae, Ashinkailepas indica Gale sp. nov. are described from a Late Pleistocene cold seep (52.6 ka), cored in the Krishna-Godavari Basin, offshore from the eastern coast of India. This constitutes the first fossil record of the genus, and its first occurrence in the Indian Ocean. Other fossil records of the Neolepadidae (here elevated to full family status) are discussed, and it is concluded that only Stipilepas molerensis from the Eocene of Denmark, is correctly referred to the family. Cladistic analysis of the Neolepadidae supports a basal position for Ashinkailepas, as deduced independently from molecular studies, and the Lower Cretaceous brachylepadid genus Pedupycnolepas is identified as sister taxon to Neolepadidae. Neolepadids are not Mesozoic relics as claimed, preserved in association with the highly specialised environments of cold seeps and hydrothermal vents, but are rather an early Cenozoic offshoot from the clade which also gave rise to the sessile cirripedes

Atomistic Hartree theory of twisted double bilayer graphene near the magic angle

Twisted double bilayer graphene (tDBLG) is a moiré material that has recently generated significant interest because of the observation of correlated phases near the magic angle. We carry out atomistic Hartree theory calculations to study the role of electron–electron interactions in the normal state of tDBLG. In contrast to twisted bilayer graphene, we find that such interactions do not result in significant doping-dependent deformations of the electronic band structure of tDBLG. However, interactions play an important role for the electronic structure in the presence of a perpendicular electric field as they screen the external field. Finally, we analyze the contribution of the Hartree potential to the crystal field, i.e. the on-site energy difference between the inner and outer layers. We find that the on-site energy obtained from Hartree theory has the same sign, but a smaller magnitude compared to previous studies in which the on-site energy was determined by fitting tight-binding results to ab initio density-functional theory (DFT) band structures. To understand this quantitative difference, we analyze the ab initio Kohn–Sham potential obtained from DFT and find that a subtle interplay of electron–electron and electron–ion interactions determines the magnitude of the on-site potential

Generation of hydrothermal Fe-Si oxyhydroxide deposit on the Southwest Indian Ridge and its implication for the origin of ancient banded iron formations

Modern hydrothermal Fe-Si oxyhydroxide deposits are now known to be analogues to ancient siliceous iron formations. In this study, samples of Fe-Si oxyhydroxide deposits were collected from hydrothermal field on the Southwest Indian Ridge. An investigation of mineralization in these deposits was carried out based on a series of mineralogical and morphological methods. X-ray diffraction and selected area electron diffraction analysis show that amorphous opal and poorly crystalline ferrihydrite are the major minerals. Furthermore, some typical filament structures detected by scanning electronic microscopy examinations, probably indicating the presence of Fe-oxidizing bacteria (FeOB), are pervasive with the main constituents being Fe, Si, P, and C. We thus believe that chemolithoautotrophic FeOB play a significant role in the formation of Fe oxyhydroxide which can effectively oxidize reduced Fe(II) sourced from hydrothermal fluids. Precipitation of amorphous silica, in contrast, is only a passive process with the Fe oxyhydroxide acting as a template. The distinct microlaminae structure alternating between the Fe-rich and Si-rich bands was observed in our samples for the first time in modern seafloor hydrothermal systems. We propose that its formation was due to the episodic temperature variation of the hydrothermal fluid which controls the biogenic Fe oxyhydroxide formation and passive precipitation of silica in this system. Our results might provide a clue for the formation mechanism of ancient banded iron formations

Reducing asymmetric information with usage-based automobile insurance

Abstract: Automobile insurers currently use available information about the vehicle, the owner and residential area when determining the probability of a claim (insurance risk). A drawback is that several risk classification variables are based on the policyholder's self-reported risk. This study highlights the fact that the information asymmetry associated with classifying risk may cause unfair premiums, since it is possible for high risk drivers to mimic low risk drivers. The aim of this paper is to explore the possibility of reducing information asymmetries by introducing a Usage Based Insurance (UBI) option where the driving behavior is monitored. While most models focus on identifying the high risk type, this approach provides an opportunity for the low risk individuals to reveal their type. The results suggest that voluntary UBI is an efficient instrument to separate risks and that the low risk drivers do not suffer the utility loss generally associated with asymmetric information. Introducing UBI as an additional contract enables full coverage at an actuarially fair premium for both types of policyholders. Besides, by reducing information asymmetries UBI can, in a wider perspective, provide incentives for the high risk driver to become a low risk driver by reducing risk-taking behavior

Who needs nature? The influence of employee speciesism on nature-based need satisfaction and subsequent work behavior

Scholars have long upheld the notion that exposure to nature benefits individuals. Recently, organizational researchers have theorized that these benefits extend to the workplace, leading to calls for organizations to incorporate contact with nature into employees’ jobs. However, it is unclear whether the effects of nature are strong enough to meaningfully impact employee performance, thereby justifying organizations’ investments in it. In this research, we draw on self-determination theory to develop a theoretical model predicting that exposure to nature at work satisfies employees’ psychological needs (i.e., needs for autonomy, relatedness, and competence), and positively affects their subsequent task performance and prosocial behavior. In addition, we theorize that the effects of nature on need satisfaction are weaker in employees higher on speciesism (i.e., the belief that humans are superior to other forms of life). We test these predictions with a mixed-method approach comprised of an online experiment in the United States (Study 1), a field experiment in Hong Kong (Study 2), a multi-wave, multi-source field study in Taiwan (Study 3), and a multi-wave, multi-source field study (with objective performance scores) in New Zealand (Study 4). Overall, our findings largely support our theoretical model

III Seminario Iberoamericano CTS1. Elección de los Órganos directivos de la Asociación Iberoamericana Ciencia Tecnología Sociedad en la Educación en Ciencias

2 página

Upper Toarcian (Lower Jurassic) marine gastropods from the Cleveland Basin, England: systematics, palaeobiogeography and contribution to biotic recovery from the early Toarcian extinction event

Here we describe a new upper Toarcian (Lower Jurassic) marine gastropod fauna from rocks of the Cleveland Basin exposed on the North Yorkshire coast of England. The fossil assemblage consists of 16 species, of which three are new: Katosira ? bicarinata sp. nov., Turritelloidea stepheni sp. nov. and Striactaenonina elegans sp. nov. Four species are described in open nomenclature as Tricarilda ? sp., Jurilda sp., Cylindrobullina sp. and Cossmannina sp. The other species have previously been described: Coelodiscus minutus (Schübler in Zieten), Procerithium quadrilineatum (Römer), Pseudokatosira undulata (Benz in von Zieten), Palaeorissoina aff. acuminata (Gründel), Pietteia unicarinata (Hudleston), Globularia cf. canina (Hudleston), Striactaeonina cf. richterorum Schulbert & Nützel, Striactaenonina aff. tenuistriata (Hudleston) and Sulcoactaeon sedgvici (Phillips). Most of these species are the earliest records of their respective genera and show palaeobiogeographical connections with contemporary gastropod associations from other regions of Europe and South America. The taxonomic composition of the upper Toarcian Cleveland Basin gastropod assemblage differs substantially from the faunas of the upper Pliensbachian and lower Toarcian Tenuicostatum Zone, showing the strong effect of the early Toarcian mass extinction event on the marine gastropod communities in the basin. Only a few gastropod species are shared between the late Toarcian faunas and the much more diverse Aalenian gastropod faunas in the Cleveland Basin, suggesting that there was a facies control on gastropod occurrences at that time. This is also a potential explanation for the taxonomic differences between the late Toarcian gastropod faunas in the Cleveland Basin and those in France, and northern and southern Germany

Eficiência da bioadição na remoção de matéria orgânica em sistemas aquaculturais

Several techniques are currently used to treat effluents. Bioaugmentation is a new bioremediation strategy and has been employed to improve effluent quality by treating the water during the production process. This technology consists basically of the addition of microorganisms able to degrade or remove polluting compounds, especially organic matter and nutrients. The objective of this study was to assess the effects of bioaugmentation on some parameters of organic matter and on the performance of juvenile tilapias in an intensive aquaculture production system. The combination of two bacterial consortiums in a complete randomized design was employed in a factorial analysis with two factors. Statistical differences between treatments were analyzed by the analysis of variance (ANOVA) and Tukey test at the 5% level. One of the treatments, heterotrophic bacterial supplementation, was able to reduce biochemical oxygen demand (BOD) by 23%, dissolved organic carbon (DOC) by 83.7% and phytoplanktonic biomass by 43%. On the other hand, no damage was done to either the physical-chemical indicators of water quality or to the growth performance of juvenile tilapias assessed in this study.Existem diversas tecnologias para tratamento de efluentes, o processo de bioadição consiste em uma vertente da biorremediação e tem sido empregado na melhoria da qualidade dos efluentes através do tratamento da água de produção. Esta tecnologia consiste basicamente na adição de microrganismos com a capacidade de degradar ou remover compostos poluentes, especialmente matéria orgânica e nutrientes. Este estudo objetivou avaliar os efeitos da suplementação de composto bioativo sobre alguns parâmetros de matéria orgânica e de desempenho de juvenis de tilápias em um sistema intensivo de produção aquacultural. Foi empregada a combinação de dois consórcios bacterianos em delineamento inteiramente aleatorizado, em um esquema fatorial com dois fatores. As diferenças estatísticas entre os tratamentos foram analisadas por meio da análise de variância (ANOVA) e do teste de Tukey ao nível de 5%. Verificou-se neste estudo, que a bioadição heterotrófica foi capaz de reduzir em 23% a demanda bioquímica de oxigênio (DBO); em 83,7%, o carbono orgânico dissolvido (COD); e em 43%, a biomassa fitoplanctônica. Por outro lado, não se observou nenhum prejuízo com relação aos parâmetros físico-químicos de qualidade de água bem como ao desempenho de crescimento para juvenis de tilápias avaliados neste estudo.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP